CYP24A1 gene and Vitamin D - many studies

Proper activation	makes sure that Vitamin D does not accumulate in the body
Too much activation	Less vitamin D actually gets to cells
Too little activation	Vitamin D accumulates to toxic levels ( <1 in 10,000 people)

Blood test does not show when a poor CYP24A1 gene stops Vitamin D from getting to cells
Click here for more information
Several Cancers and health problems appear to protect themselves by changing CYP24A1 activation

---

---

39+ VitaminDWiki pages with CYP24A1 in title

This list is automatically updated

---

11+ VitaminDWiki pages with both CYP24A1 AND CANCER in the title

This list is automatically updated

---

CYP24A1: cancer, autoimmune and inflamation via genetics and epigenetics - Oct 2024

Regulatory Mechanisms and Pathological Implications of CYP24A1 in Vitamin D Metabolism
Pathology - Research and Practice
https://doi.org/10.1016/j.prp.2024.155684 a portion of the PDF is online
KL Milan, KM Ramkumar

CYP24A1 is a crucial gene within the cytochrome P450 superfamily, responsible for encoding the enzyme 25-hydroxyvitamin D3-24-hydroxylase. This enzyme is involved in the catabolism of 1,25-dihydroxyvitamin D3, the biologically active form of vitamin D3, by hydroxylating its side chain. Through this process, CYP24A1 tightly regulates the bioavailability and physiological impact of vitamin D3 in the body.
Dysregulation of CYP24A1, particularly its overexpression, has been increasingly associated with the progression of various diseases, including

• cancers,
• autoimmune disorders, and
• chronic inflammatory conditions.

Elevated levels of CYP24A1 can lead to excessive degradation of vitamin D3, resulting in diminished levels of this critical hormone, which is essential for calcium homeostasis, immune function, and cellular proliferation. This review explores into the structural characteristics of CYP24A1, exploring how it influences its enzymatic activity. Furthermore, it examines the expression patterns of CYP24A1 across different diseases, emphasizing the enzyme's role in disease pathology. The review also discusses the regulatory mechanisms governing CYP24A1 expression, including

• genetic mutations,
• epigenetic modifications, and
• metabolite-mediated regulation.

By understanding these mechanisms, the review provides insight into the potential therapeutic strategies that could target CYP24A1, aiming to alleviate its overexpression and restore vitamin D3 balance in disease states.

---

Antioxident Glutathione helps CYP24A1

---

Rare CYP24A1 variant results in hypercalcemia in infants - Sept 2023

__Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant
J Pediatr Endocrinol Metab . 2023 Sep 29. doi: 10.1515/jpem-2023-0147
Zhichao Zheng 1, Yujie Wu 2, Huiping Wu 1, Jiahui Jin 1, Yue Luo 1, Shunshun Cao 1, Xiaoou Shan 1

Objectives: Infantile hypercalcemia-1(HCINF1) is a rare disease caused by pathogenic variants in the CYP24A1 gene, resulting in the inability to metabolize active vitamin D. This leads to hypercalcemia and severe complications.

Content: On December 8th, 2022, a systematic literature search was conducted in PubMed, Wanfang, and CNKI using the keywords "hypercalcemia" and "CYP24A1". Data extraction included patient demographics, clinical presentation, treatment medications, and outcomes. The findings were synthesized to identify common patterns and variations among cases and to assess the efficacy of different therapies in reducing serum calcium. Our findings revealed two distinct peaks in the incidence of HCINF1 caused by CYP24A1 pathogenic variant.
Kidney stones or renal calcifications were the most common clinical manifestations of the disease, followed by polyuria and developmental delay. Laboratory investigations showed hypercalcemia, elevated vitamin D levels, hypercalciuria, and low parathyroid hormone. Genetic analysis remains the only reliable diagnostic tool. Although there is no definitive cure for HCINF1, multiple drugs, including bisphosphonates, calcitonin, and rifampicin, have been used to control its symptoms. Blocking the production and intake of vitamin D is the preferred treatment option.

Summary and outlook: Our review highlights the basic clinical and biochemical features of HCINF1 and suggests that targeted diagnostic and therapeutic strategies are needed to address the clinical heterogeneity of the disease. The insights gained from this study may facilitate the development of innovative treatments for HCINF1.
References

1. Hmami, F, Oulmaati, A, Amarti, A, Kottler, ML, Bouharrou, A. Overdose or hypersensitivity to vitamin D? Arch Pediatr 2014;21:1115–9. https://doi.org/10.1016/j.arcped.2014.06.025 . - DOI
2. Brancatella, A, Cappellani, D, Kaufmann, M, Semeraro, A, Borsari, S, Sardella, C, et al.. Long-term efficacy and safety of Rifampin in the treatment of a patient carrying a CYP24A1loss-of-function variant. J Clin Endocrinol Metab 2022;107:e3159–66. https://doi.org/10.1210/clinem/dgac315 . - DOI
3. Schlingmann, KP, Ruminska, J, Kaufmann, M, Dursun, I, Patti, M, Kranz, B, et al.. Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. J Am Soc Nephrol 2016;27:604–14. https://doi.org/10.1681/asn.2014101025 . - DOI
4. Azer, SM, Vaughan, LE, Tebben, PJ, Sas, DJ. 24-Hydroxylase deficiency due to CYP24A1sequence variants: comparison with other vitamin D-mediated hypercalcemia disorders. J Endocr Soc 2021;5:bvab119. https://doi.org/10.1210/jendso/bvab119 . - DOI
5. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71 . - DOI
6. Nesterova, G, Malicdan, MC, Yasuda, K, Sakaki, T, Vilboux, T, Ciccone, C, et al.. 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 2013;8:649–57. https://doi.org/10.2215/cjn.05360512 . - DOI
7. Schlingmann, KP, Kaufmann, M, Weber, S, Irwin, A, Goos, C, John, U, et al.. Mutations in CYP24A1and idiopathic infantile hypercalcemia. N Engl J Med 2011;365:410–21. https://doi.org/10.1056/nejmoa1103864 . - DOI
8. Streeten, EA, Zarbalian, K, Damcott, CM. CYP24A1mutations in idiopathic infantile hypercalcemia. N Engl J Med 2011;365:17412–23. https://doi.org/10.1056/NEJMc1110226 . - DOI
9. Dauber, A, Nguyen, TT, Sochett, E, Cole, DEC, Horst, R, Abrams, SA, et al.. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 2012;97:E268–74. https://doi.org/10.1210/jc.2011-1972 . - DOI
10. Tebben, PJ, Milliner, DS, Horst, RL, Harris, PC, Singh, RJ, Wu, Y, et al.. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012;97:E423–7. https://doi.org/10.1210/jc.2011-1935 . - DOI
11. Skalova, S, Cerna, L, Bayer, M, Kutilek, S, Konrad, M, Schlingmann, KP. Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. Iran J Kidney Dis 2013;7:160–4.
12. Castanet, M, Mallet, E, Kottler, ML. Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations. J Pediatr 2013;163:1208–10. https://doi.org/10.1016/j.jpeds.2013.04.056 . - DOI
13. Dinour, D, Beckerman, P, Ganon, L, Tordjman, K, Eisenstein, Z, Holtzman, EJ. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 2013;190:552–7. https://doi.org/10.1016/j.juro.2013.02.3188 . - DOI
14. Meusburger, E, Mündlein, A, Zitt, E, Obermayer-Pietsch, B, Kotzot, D, Lhotta, K. Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcaemia and a novel CYP24A1mutation. Clin Kidney J 2013;6:211–15. https://doi.org/10.1093/ckj/sft091 . - DOI
15. Wolf, P, Müller-Sacherer, T, Baumgartner-Parzer, S, Winhofer, Y, Kroo, J, Gessl, A, et al.. A case of “Late-Onset” idiopathic infantile hypercalcemia secondary to mutations in the CYP24A1gene. Endocr Pract 2014;20:e91–5. https://doi.org/10.4158/ep13479.cr . - DOI
16. Jacobs, TP, Kaufman, M, Jones, G, Kumar, R, Schlingmann, KP, Shapses, S, et al.. A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab 2014;99:708–12. https://doi.org/10.1210/jc.2013-3802 . - DOI
17. Dowen, FE, Sayers, JA, Hynes, AM, Sayer, JA. CYP24A1mutation leading to nephrocalcinosis. Kidney Int 2014;85:1475. https://doi.org/10.1038/ki.2013.416 . - DOI
18. Colussi, G, Ganon, L, Penco, S, De Ferrari, ME, Ravera, F, Querques, M, et al.. Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transpl 2014;29:636–43. https://doi.org/10.1093/ndt/gft460 . - DOI
19. Helmuth, A, Konrad, M, Schlingmann, KP, Pasch, A. The case | hypercalcemia in a 60-year-old male. Kidney Int 2014;85:219–21. https://doi.org/10.1038/ki.2013.184 . - DOI
20. Molin, A, Baudoin, R, Kaufmann, M, Souberbielle, JC, Ryckewaert, A, Vantyghem, MC, et al.. CYP24A1mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J Clin Endocrinol Metab 2015;100:E1343–52. https://doi.org/10.1210/jc.2014-4387 . - DOI
21. Cools, M, Goemaere, S, Baetens, D, Raes, A, Desloovere, A, Kaufman, J, et al.. Calcium and bone homeostasis in heterozygous carriers of CYP24A1mutations: a cross-sectional study. Bone 2015;81:89–96. https://doi.org/10.1016/j.bone.2015.06.018 . - DOI
22. Jobst-Schwan, T, Pannes, A, Schlingmann, KP, Eckardt, KU, Beck, BB, Wiesener, MS. Discordant clinical course of vitamin-D-hydroxylase (CYP24A1) associated hypercalcemia in two adult brothers with nephrocalcinosis. Kidney Blood Press Res 2015;40:443–51. https://doi.org/10.1159/000368520 . - DOI
23. Tray, KA, Laut, J, Saidi, A. Idiopathic infantile hypercalcemia, presenting in adulthood--No longer idiopathic nor infantile: two case reports and review. Conn Med 2015;79:593–7.
24. Figueres, ML, Linglart, A, Bienaime, F, Allain-Launay, E, Roussey-Kessler, G, Ryckewaert, A, et al.. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1mutations. Am J Kidney Dis 2015;65:122–6. https://doi.org/10.1053/j.ajkd.2014.06.037 . - DOI
25. Shah, AD, Hsiao, EC, O’Donnell, B, Salmeen, K, Nussbaum, R, Krebs, M, et al.. Maternal hypercalcemia due to failure of 1,25-dihydroxyvitamin-D3 catabolism in a patient with CYP24A1mutations. J Clin Endocrinol Metab 2015;100:2832–6. https://doi.org/10.1210/jc.2015-1973 . - DOI
26. Dinour, D, Davidovits, M, Aviner, S, Ganon, L, Michael, L, Modan-Moses, D, et al.. Maternal and infantile hypercalcemia caused by vitamin-D-hydroxylase mutations and vitamin D intake. Pediatr Nephrol 2015;30:145–52. https://doi.org/10.1007/s00467-014-2889-1 . - DOI
27. Woods, GN, Saitman, A, Gao, H, Clarke, NJ, Fitzgerald, RL, Chi, NW. A young woman with recurrent gestational hypercalcemia and acute pancreatitis caused by CYP24A1deficiency. J Bone Min Res 2016;31:1841–4. https://doi.org/10.1002/jbmr.2859 . - DOI
28. O’Keeffe, DT, Tebben, PJ, Kumar, R, Singh, RJ, Wu, Y, Wermers, RA. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1mutations: evidence of gene dose effect. Osteoporos Int 2016;27:3121–5. https://doi.org/10.1007/s00198-016-3615-6 . - DOI
29. Loyer, C, Leroy, C, Molin, A, Odou, MF, Huglo, D, Lion, G, et al.. Hyperparathyroidism complicating CYP 24A1 mutations. Ann Endocrinol 2016;77:615–19. https://doi.org/10.1016/j.ando.2016.03.002 . - DOI
30. Marks, BE, Doyle, DA. Idiopathic infantile hypercalcemia: case report and review of the literature. J Pediatr Endocrinol Metab 2016;29:127–32. https://doi.org/10.1515/jpem-2015-0133 . - DOI
31. Gigante, M, Santangelo, L, Diella, S, Caridi, G, Argentiero, L, D’’Alessandro, MM, et al.. Mutational spectrum of CYP24A1gene in a cohort of Italian patients with idiopathic infantile hypercalcemia. Nephron 2016;133:193–204. https://doi.org/10.1159/000446663 . - DOI
32. Ertl, DA, Raimann, A, Csaicsich, D, Patsch, JM, Laccone, F, Haeusler, G. A pediatric patient with a CYP24A1mutation: four years of clinical, biochemical, and imaging follow-up. Horm Res Paediatr 2017;87:196–204. https://doi.org/10.1159/000450947 . - DOI
33. Ferraro, PM, Minucci, A, Primiano, A, De Paolis, E, Gervasoni, J, Persichilli, S, et al.. A novel CYP24A1genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass. Urolithiasis 2017;45:291–4. https://doi.org/10.1007/s00240-016-0923-4 . - DOI
34. Pronicka, E, Ciara, E, Halat, P, Janiec, A, Wójcik, M, Rowińska, E, et al.. Biallelic mutations in CYP24A1or SLC34A1 as a cause of infantile idiopathic hypercalcemia (IIH) with vitamin D hypersensitivity: molecular study of 11 historical IIH cases. J Appl Genet 2017;58:349–53. https://doi.org/10.1007/s13353-017-0397-2 . - DOI
35. Hawkes, CP, Li, D, Hakonarson, H, Meyers, KE, Thummel, KE, Levine, MA. CYP3A4 induction by Rifampin: an alternative pathway for vitamin D inactivation in patients with CYP24A1mutations. J Clin Endocrinol Metab 2017;102:1440–6. https://doi.org/10.1210/jc.2016-4048 . - DOI
36. Baudart, P, Molin, A, Cesini, J, Jones, G, Kaufmann, M, Kottler, ML, et al.. Calcium pyrophosphate deposition disease revealing a hypersensitivity to vitamin D. Jt Bone Spine 2017;84:349–51. https://doi.org/10.1016/j.jbspin.2016.11.006 . - DOI
37. Seidowsky, A, Villain, C, Vilaine, E, Baudoin, R, Tabarin, A, Kottler, ML, et al.. Hypercalcemia and inactive mutation of CYP24A1. Case-study and literature review. Néphrol Thér 2017;13:146–53. https://doi.org/10.1016/j.nephro.2017.01.019 . - DOI
38. Madsen, J, Sauer, S, Beck, B, Johannesen, J. CYP24A1mutation in a girl infant with idiopathic infantile hypercalcemia. J Clin Res Pediatr Endocrinol 2018;10:83–6. https://doi.org/10.4274/jcrpe.4841 . - DOI
39. Silvestre, C, Aragües, JM, Bugalho, MJ, Jones, G, Kaufmann, M. Idiopathic infantile hypercalcemia presenting in childhood but diagnosed in adulthood. AACE Clin Case Rep 2018;4:256–62. https://doi.org/10.4158/accr-2017-0108 . - DOI
40. Schlingmann, KP, Cassar, W, Konrad, M. Juvenile onset IIH and CYP24A1mutations. Bone Rep 2018;9:42–6. https://doi.org/10.1016/j.bonr.2018.06.005 . - DOI
41. Sun, Y, Shen, J, Hu, X, Qiao, Y, Yang, J, Shen, Y, et al.. CYP24A1variants in two Chinese patients with idiopathic infantile hypercalcemia. Fetal Pediatr Pathol 2019;38:44–56. https://doi.org/10.1080/15513815.2018.1492052 . - DOI
42. Cappellani, D, Brancatella, A, Kaufmann, M, Minucci, A, Vignali, E, Canale, D, et al.. Hereditary hypercalcemia caused by a homozygous pathogenic variant in the CYP24A1gene: a case report and review of the literature. Case Rep Endocrinol 2019;2019:4982621. https://doi.org/10.1155/2019/4982621 . - DOI
43. Arnold, N, O’Toole, V, Huynh, T, Smith, HC, Luxford, C, Clifton-Bligh, R, et al.. Intractable hypercalcaemia during pregnancy and the postpartum secondary to pathogenic variants in CYP24A1. Endocrinol Diabetes Metab Case Rep 2019;2019. https://doi.org/10.1530/edm-19-0114 . - DOI
44. Molin, A, Nowoczyn, M, Coudray, N, Ballandone, C, Abéguilé, G, Mittre, H, et al.. Molecular characterization of a recurrent 10.9 kb CYP24A1deletion in idiopathic infantile hypercalcemia. Eur J Med Genet 2019;62:103577. https://doi.org/10.1016/j.ejmg.2018.11.011 . - DOI
45. Jiráčková, J, Hyšpler, R, Alkanderi, S, Pavlíková, L, Palicka, V, Sayer, JA. Novel CYP24A1mutation in a young male patient with nephrolithiasis: case report. Kidney Blood Press Res 2019;44:870–7. https://doi.org/10.1159/000500922 . - DOI
46. Hedberg, F, Pilo, C, Wikner, J, Törring, O, Calissendorff, J. Three sisters with heterozygous gene variants of CYP24A1: maternal hypercalcemia, new-onset hypertension, and neonatal hypoglycemia. J Endocr Soc 2019;3:387–96. https://doi.org/10.1210/js.2018-00337 . - DOI
47. Güven, A, Konrad, M, Schlingmann, KP. Idiopathic infantile hypercalcemia: mutations in SLC34A1 and CYP24A1in two siblings and fathers. J Pediatr Endocrinol Metab 2020;33:1353–8. https://doi.org/10.1515/jpem-2020-0169 . - DOI
48. Mirea, AM, Pop, RM, Căinap, SS, Trifa, AP. Presymptomatic diagnosis of CYP24A1-related infantile idiopathic hypercalcemia: a case report. Eur J Med Genet 2020;63:104100. https://doi.org/10.1016/j.ejmg.2020.104100 . - DOI
49. David, K, Khalil, R, Hannon, H, Evenepoel, P, Decallonne, B. Therapy-resistant hypercalcemia in a patient with inactivating CYP24A1mutation and recurrent nephrolithiasis: beware of concomitant hyperparathyroidism. Calcif Tissue Int 2020;107:524–8. https://doi.org/10.1007/s00223-020-00738-8 . - DOI
50. Rousseau-Nepton, I, Jones, G, Schlingmann, K, Kaufmann, M, Zuijdwijk, CS, Khatchadourian, K, et al.. CYP24A1and SLC34A1 pathogenic variants are uncommon in a Canadian cohort of children with hypercalcemia or hypercalciuria. Horm Res Paediatr 2021;94:124–32. https://doi.org/10.1159/000517548 . - DOI
51. Gurevich, E, Levi, S, Borovitz, Y, Alfandary, H, Ganon, L, Dinour, D, et al.. Childhood hypercalciuric hypercalcemia with elevated vitamin D and suppressed parathyroid hormone: long-term follow up. Front Pediatr 2021;9:752312. https://doi.org/10.3389/fped.2021.752312 . - DOI
52. Brancatella, A, Cappellani, D, Kaufmann, M, Borsari, S, Piaggi, P, Baldinotti, F, et al.. Do the heterozygous carriers of a CYP24A1mutation display a different biochemical phenotype than wild types. J Clin Endocrinol Metab 2021;106:708–17. https://doi.org/10.1210/clinem/dgaa876 . - DOI
53. De Bonis, M, De Paolis, E, Onori, ME, Mazzuccato, G, Gatto, A, Ferrara, P, et al.. Duplex high resolution melting analysis (dHRMA) to detect two hot spot CYP24A1pathogenic variants (PVs) associated to idiopathic infantile hypercalcemia (IIH). Mol Biol Rep 2021;48:3303–11. https://doi.org/10.1007/s11033-021-06324-x . - DOI
54. Romašovs, A, Jaunozola, L, Berga-Švītiņa, E, Daneberga, Z, Miklaševičs, E, Pīrāgs, V. Hypercalcemia and CYP24A1gene mutation diagnosed in the 2nd trimester of a twin pregnancy: a case report. Am J Case Rep 2021;22:e931116. https://doi.org/10.12659/ajcr.931116 . - DOI
55. Lenherr-Taube, N, Young, EJ, Furman, M, Elia, Y, Assor, E, Chitayat, D, et al.. Mild idiopathic infantile hypercalcemia-Part 1: biochemical and genetic findings. J Clin Endocrinol Metab 2021;106:2915–37. https://doi.org/10.1210/clinem/dgab431 . - DOI
56. Molin, A, Lemoine, S, Kaufmann, M, Breton, P, Nowoczyn, M, Ballandonne, C, et al.. Overlapping phenotypes associated with CYP24A1, SLC34A1, and SLC34A3 mutations: a cohort study of patients with hypersensitivity to vitamin D. Front Endocrinol 2021;12:736240. https://doi.org/10.3389/fendo.2021.736240 . - DOI
57. Hureaux, M, Chantot-Bastaraud, S, Cassinari, K, Martinez Casado, E, Cuny, A, Frébourg, T, et al.. When a maternal heterozygous mutation of the CYP24A1gene leads to infantile hypercalcemia through a maternal uniparental disomy of chromosome 20. Mol Cytogenet 2021;14:23. https://doi.org/10.1186/s13039-021-00543-4 . - DOI
58. Györkös, A, Tőke, J, Sohár, G, Kovács, M, Goldfinger, J, Vajda, G, et al.. A CYP24A1-gén terhességi hypercalcaemiát okozó defektusa. Orv Hetil 2022;163:1237–42. https://doi.org/10.1556/650.2022.32520 . - DOI
59. Brunerova, L, Remes, O, Zoubkova, V, Votypka, P. Case report: two heterozygous pathogenic variants of CYP24A1: a novel cause of hypercalcemia and nephrocalcinosis in adulthood. Front Med 2022;9:1020096. https://doi.org/10.3389/fmed.2022.1020096 . - DOI
60. Granhøj, J, Tougaard, B, Lildballe, DL, Rasmussen, M. Family history is important to identify patients with monogenic causes of adult-onset chronic kidney disease. Nephron 2022;146:49–57. https://doi.org/10.1159/000518175 . - DOI
61. Pilz, S, Theiler-Schwetz, V, Pludowski, P, Zelzer, S, Meinitzer, A, Karras, SN, et al.. Hypercalcemia in pregnancy due to CYP24A1mutations: case report and review of the literature. Nutrients 2022;14. https://doi.org/10.3390/nu14122518 . - DOI
62. Lefèvre, CR, Peltier, L, Lokchine, A, Ryckewaert, A, Moreau, C. Rare cause of life-threatening hypercalcemia in an infant: a case report. Ann Biol Clin 2022;80:460–3. https://doi.org/10.1684/abc.2022.1747 . - DOI
63. Guimei, L, Yan, S, Xiaohong, S, Ping, Z, Lin, T. CYP24A1mutation causes severe idiopathic infantile hypercalcemia. In: The seventeenth national pediatric academic conference of the Chinese medical association . Chinese Medical Association; 2012:653 p.
64. Xinyan, R, Yongming, S. A case of idiopathic hypercalcemia due to mutation in the infant CYP24A1gene. Chin J Eugen Genet 2016;24:124.
65. Sayers, J, Hynes, AM, Srivastava, S, Dowen, F, Quinton, R, Datta, HK, et al.. Successful treatment of hypercalcaemia associated with a CYP24A1mutation with fluconazole. Clin Kidney J 2015;8:453–5. https://doi.org/10.1093/ckj/sfv028 . - DOI
66. McBride, L, Houlihan, C, Quinlan, C, Messazos, B, Stark, Z, Crosthwaite, A. Outcomes following treatment of maternal hypercalcemia due to CYP24A1pathogenic variants. Kidney Int Rep 2019;4:888–92. https://doi.org/10.1016/j.ekir.2019.02.018 . - DOI
67. Griffin, TP, Joyce, CM, Alkanderi, S, Blake, LM, O’Keeffe, DT, Bogdanet, D, et al.. Biallelic CYP24A1variants presenting during pregnancy: clinical and biochemical phenotypes. Endocr Connect 2020;9:530–41. https://doi.org/10.1530/ec-20-0150 . - DOI
68. Macdonald, C, Upton, T, Hunt, P, Phillips, I, Kaufmann, M, Florkowski, C, et al.. Vitamin D supplementation in pregnancy: a word of caution. Familial hypercalcaemia due to disordered vitamin D metabolism. Ann Clin Biochem 2020;57:186–91. https://doi.org/10.1177/0004563219897691 . - DOI
69. Zheng, Z, Wu, Y, Wu, H, Jin, J, Luo, Y, Cao, S, et al.. Successful treatment of hypercalcemia in a Chinese patient with a novel homozygous mutation in the CYP24A1gene using zoledronic acid: a case report. J Pediatr Endocrinol Metab 2023. https://doi.org/10.1515/jpem-2023-0212 . - DOI
70. Ferraro, PM, Minucci, A, Primiano, A, De Paolis, E, Gervasoni, J, Persichilli, S, et al.. Erratum to: a novel CYP24A1genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass. Urolithiasis 2017;45:295. https://doi.org/10.1007/s00240-016-0940-3 . - DOI
71. Kaufmann, M, Morse, N, Molloy, BJ, Cooper, DP, Schlingmann, KP, Molin, A, et al.. Improved screening test for idiopathic infantile hypercalcemia confirms Residual levels of serum 24,25-(OH)(2) D(3) in affected patients. J Bone Min Res 2017;32:1589–96. https://doi.org/10.1002/jbmr.3135 . - DOI
72. Davies, M, Mawer, EB, Freemont, AJ. The osteodystrophy of hypervitaminosis D: a metabolic study. Q J Med 1986;61:911–9.
73. St-Arnaud, R, Arabian, A, Travers, R, Barletta, F, Raval-Pandya, M, Chapin, K, et al.. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000;141:2658–66. https://doi.org/10.1210/endo.141.7.7579 . - DOI
74. Akeno, N, Matsunuma, A, Maeda, T, Kawane, T, Horiuchi, N. Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 2000;164:339–48. https://doi.org/10.1677/joe.0.1640339 . - DOI
75. Dhawan, P, Christakos, S. Novel regulation of 25-hydroxyvitamin D3 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBP beta, and the Vitamin D receptor in 24(OH)ase transcription. J Cell Biochem 2010;110:1314–23. https://doi.org/10.1002/jcb.22645 . - DOI
76. Curtis, KM, Aenlle, KK, Roos, BA, Howard, GA. 24R,25-dihydroxyvitamin D3 promotes the osteoblastic differentiation of human mesenchymal stem cells. Mol Endocrinol 2014;28:644–58. https://doi.org/10.1210/me.2013-1241 . - DOI
77. Zayny, A, Almokhtar, M, Wikvall, K, Ljunggren, Ö, Ubhayasekera, K, Bergquist, J, et al.. Effects of glucocorticoids on vitamin D(3)-metabolizing 24-hydroxylase (CYP24A1) in Saos-2 cells and primary human osteoblasts. Mol Cell Endocrinol 2019;496:110525. https://doi.org/10.1016/j.mce.2019.110525 . - DOI
78. Hidalgo, AA, Trump, DL, Johnson, CS. Glucocorticoid regulation of the vitamin D receptor. J Steroid Biochem Mol Biol 2010;121:372–5. https://doi.org/10.1016/j.jsbmb.2010.03.081 . - DOI
79. Davidson, TG. Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 2001;58:S8–15. https://doi.org/10.1093/ajhp/58.suppl_3.s8 . - DOI
80. Dufek, S, Seidl, R, Schmook, M, Arbeiter, K, Müller-Sacherer, T, Heindl-Rusai, K. Intracranial hypertension in siblings with infantile hypercalcemia. Neuropediatrics 2015;46:49–51. https://doi.org/10.1055/s-0034-1389900 . - DOI
81. Davidson Peiris, E, Wusirika, R. A case report of compound heterozygous CYP24A1mutations leading to nephrolithiasis successfully treated with ketoconazole. Case Rep Nephrol Dial 2017;7:167–71. https://doi.org/10.1159/000485243 . - DOI
82. Trutin, I, Škorić, I. AN infant with idiopathic hypercalciuria and nephrolithiasis associated with CYP24A1enzyme polymorphism: a case report. Acta Clin Croat 2022;60:544–7. https://doi.org/10.20471/acc.2021.60.03.27 . - DOI
83. Vescini, F, Buffa, A, La Manna, G, Ciavatti, A, Rizzoli, E, Bottura, A, et al.. Long-term potassium citrate therapy and bone mineral density in idiopathic calcium stone formers. J Endocrinol Invest 2005;28:218–22. https://doi.org/10.1007/bf03345376 . - DOI

---

Many cancers increase the activation of the CYP24A1 gene – Feb 2023

Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy
Med Mol Morphol . 2023 Feb 7. doi: 10.1007/s00795-023-00348-x Publisher wants $39 for the PDF
Sakura Kamiya 1, Yuna Nakamori 1 2, Akira Takasawa 1, Kumi Takasawa 1, Daisuke Kyuno 1, Yusuke Ono 1, Kazufumi Magara 1, Makoto Osanai 3

In this review, we discuss the possibility of the vitamin D metabolizing enzyme CYP24A1 being a therapeutic target for various tumors including breast, colorectal and prostate tumors. Given the pleiotropic cellular activity of vitamin D, its deficiency impairs its physiological function in target cells and results in various pathologies including cancer. In addition, accumulated data have shown that elevated expression of CYP24A1 promotes carcinogenesis in various cancer subtypes by decreasing the bioavailability of vitamin D metabolites.
Thus, we propose the potential feasibility of vitamin D metabolism-blocking therapy in various types of human malignancies that express constitutive CYP24A1.
References

1. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009) Vitamin D: an evidence-based review. J Am Board Fam Med 22:698–760
2. Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289(1):8–28
3. Bikle DD (2021) Vitamin D: Production, Metabolism and Mechanisms of Action. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP (eds). South Dartmouth (MA): MDText.com
4. Kim D (2017) The role of vitamin D in thyroid diseases. Int J Mol Sci 18:1949
5. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G (2016) Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96(1):365–408
6. Trump DL, Aragon-Ching JB (2018) Vitamin D in prostate cancer. Asian J Androl 20(3):244–252
7. Zhou J, Ge X, Fan X, Wang J, Miao L, Hang D (2021) Associations of vitamin D status with colorectal cancer risk and survival. Int J Cancer 149:606–614
8. Negri M, Gentile A, de Angelis C, Montò T, Patalano R, Colao A, Pivonello R, Pivonello C (2020) Vitamin D-induced molecular mechanisms to potentiate cancer therapy and to reverse drug-resistance in cancer cells. Nutrients 12:1798
9. Kamiya S, Nakamori Y, Takasawa A, Takasawa K, Kyuno D, Ono Y, Magara K, Osanai M (2023) Suppression of vitamin D metabolizing enzyme CYP24A1 provides increased sensitivity to chemotherapeutic drugs in breast cancer. Oncol Rep, in press.
10. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
11. Kerr JFR, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–257
12. Sergeev IN (2014) Vitamin D-mediated apoptosis in cancer and obesity. Horm Mol Biol Clin Investig 20:43–49
13. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87
14. Rajendran V, Jain MV (2018) In vitro tumorigenic assay: colony forming assay for cancer stem cells. Methods Mol Biol 1692:89–95
15. Luo W, Johnson CS, Trump DL (2016) Vitamin D signaling modulators in cancer therapy. In: Litwack G (ed) Vitamins & Hormones. Academic Press, Cambridge
16. Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M (2005) Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 11:3579–3586
17. Osanai M, Lee G (2016) CYP24A1-induced vitamin D insufficiency promotes breast cancer growth. Oncol Rep 36:2755–2762
18. Nakajima M, Yokoi T (2014) MicroRNA: regulation of P450 and pharmacogenetics. In: Padmanabhan S (ed) Handbook of pharmacogenomics and stratified medicine. Academic Press, Cambridge, pp 385–401
19. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T (2009) Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 76:702–709
20. Matilainen JM, Malinen M, Turunen MM, Carlberg C, Väisänen S (2010) The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells. J Biol Chem 285:24174–24183
21. Grant WB, Garland CF (2004) A critical review of studies on vitamin D in relation to colorectal cancer. Nutr Cancer 48:115–123
22. Giovannucci E (2006) The epidemiology of vitamin D and colorectal cancer: recent findings. Curr Opin Gastroenterol 22:24–29
23. Klampfer L (2014) Vitamin D and colon cancer. World J Gastrointest Oncol 6:430–437
24. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A (2000) Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60:2304–2312
25. Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF (2001) 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 357:1673–1674
26. Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, White E, Slattery ML, Farin FM, Makar KW, Carlson CS, Caan BJ, Potter JD, Peters U (2009) Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 18:2540–2548
27. Höbaus J, Hummel DM, Thiem U, Fetahu IS, Aggarwal A, Müllauer L, Heller G, Egger G, Mesteri I, Baumgartner-Parzer S, Kallay E (2013) Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer 133:1380–1388
28. Jacobs ET, Pelt CV, Forster RE, Zaidi W, Hibler EA, Galligan MA, Haussler MR, Jurutka PW (2013) CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res 73:2563–2573
29. Sadeghi H, Nazemalhosseini-Mojarad E, Yassaee VR, Savabkar S, Ghasemian M, Aghdaei HA, Zali MR, Mirfakhraie R (2020) Could CYP24A1 promoter methylation status affect the gene expression in the colorectal cancer patients. Meta Gene 24:100656
30. Höbaus J, Fetahu ISh, Khorchide M, Manhardt T, Kallay E (2013) Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells. J Steroid Biochem Mol Biol 136:296–299
31. Fang Z, Xiong Y, Zhang C, Li J, Liu L, Li M, Zhang W, Wan J (2010) Coexistence of copy number increases of ZNF217 and CYP24A1 in colorectal cancers in a Chinese population. Oncol Lett 1:925–930
32. Roff A, Wilson RT (2008) A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol 112:47–54
33. Chai L, Ni J, Ni X, Zhang N, Liu Y, Ji Z, Zhao X, Zhu X, Zhao B, Xin G, Wang Y, Yang F, Sun L, Zhu X, Bao W, Shui X, Wang F, Chen F, Yang Z (2021) Association of CYP24A1 gene polymorphism with colorectal cancer in the Jiamusi population. PLoS ONE 16:e0253474
34. Sadeghi H, Nazemalhosseini-Mojarad E, Yaghoob-Taleghani M, Amin-Beidokhti M, Yassaee VR, Aghdaei HA, Zali MR, Mirfakhraie R (2018) miR-30a promoter variation contributes to the increased risk of colorectal cancer in an Iranian population. J Cell Biochem. https://doi.org/10.1002/jcb.28047 - DOI
35. Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL (2010) Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 70:5953–5962
36. Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL (2011) Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 6:994–1000
37. Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, Down T, Beck S, Fournier T, Evain-Brion D, Dimitriadis E, Craig JM, Morley R, Saffery R (2009) Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 284:14838–14848
38. Ramnath N, Nadal E, Jeon CK, Sandoval J, Colacino J, Rozek LS, Christensen PJ, Esteller M, Beer DG, Kim SH (2014) Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma. J Thorac Oncol 4:473–482
39. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA (1995) Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997–1003
40. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J (1999) Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20:22–45
41. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB, For the Prostate, Lung, Colorectal, and Ovarian Trial Project Team (2007) Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 16:2623–2630
42. Tannour-Louet M, Lewis SK, Louet JF, Stewart J, Addai JB, Sahin A, Vangapandu HV, Lewis AL, Dittmar K, Pautler RG, Zhang L, Smith RG, Lamb DJ (2014) Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB J 28:364–372
43. Farhan H, Wahala K, Cross HS (2003) Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 84:423–429
44. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D (2007) Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr 137(1 Suppl):205–210
45. Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, Lin Y, Diergaarde B, Hershberger PA (2012) CYP24 inhibition preserves 1a,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol 355:153–161
46. Ly LH, Zhao XY, Holloway L, Feldman D (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071–2076
47. Zhao J, Tan BK, Marcelis S, Verstuyf A, Bouillon R (1996) Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific. J Steroid Biochem Mol Biol 57:197–202
48. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD (2002) Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 132:3191–3194
49. Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ, Lund K, Barry CP, Rodriguez IV, Pike JW, Conrads TP, Darcy KM, Maxwell GL, Hamilton CA, Syed V, Thaete LG (2016) Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: an opportunity for chemoprevention. Gynecol Oncol 143:159–167
50. Lee LR, Teng PN, Nguyen H, Hood BL, Kavandi L, Wang G, Turbov JM, Thaete LR, Hamilton CA, Maxwell GL, Rodriguez GC, Conrads TP, Syed V (2013) Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells. Cancer Prev Res (Phila) 6:731–743
51. Lou YR, Tuohimaa P (2006) Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells. J Steroid Biochem Mol Biol 99:44–49
52. Yee SW, Campbell MJ, Simons C (2006) Inhibition of Vitamin D3 metabolism enhances VDR signaling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 98:228–235
53. Josephia R, Muindi W-D, Yingyu M, Engler KL, Kong RX, Trump DL, Johnson CS (2010) CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinol 151:4301–4312
54. Dovnik A, Dovnik NF (2020) Vitamin D and ovarian cancer: systematic review of the literature with a focus on molecular mechanisms. Cells. https://doi.org/10.3390/cells9020335 - DOI

---

CYP24A1 and Vitamin D - 2011

25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D.
Arch Biochem Biophys. 2012 Jul 1;523(1):9-18. doi: 10.1016/j.abb.2011.11.003
Jones G1, Prosser DE, Kaufmann M.
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada K7L 3N6. gj1 at queensu.ca

CYP24A1 is the cytochrome P450 component of the 25-hydroxyvitamin D(3)-24-hydroxylase enzyme that catalyzes the conversion of 25-hydroxyvitamin D(3) (25-OH-D(3)) and 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) into 24-hydroxylated products, which constitute the degradation of the vitamin D molecule. This review focuses on recent data in the CYP24A1 field, including biochemical, physiological and clinical developments. Notable among these are: the first crystal structure for rat CYP24A1; mutagenesis studies which change the regioselectivity of the enzyme; and the finding that natural inactivating mutations of CYP24A1 cause the genetic disease idiopathic infantile hypercalcemia (IIH). The review also discusses the emerging correlation between rising serum phosphate/FGF-23 levels and increased CYP24A1 expression in chronic kidney disease, which in turn underlies accelerated degradation of both serum 25-OH-D(3) and 1,25-(OH)(2)D(3) in this condition. This review concludes by evaluating the potential clinical utility of blocking this enzyme with CYP24A1 inhibitors in various disease states.
Outline
CYP24A1: biochemistry and catalytic properties
CYP24A1: crystal structure, homology modeling and mutagenesis studies
CYP24A1: physiological role
CYP24A1: regulation by 1,25-(OH)2D3, PTH and FGF-23
CYP24A1: pharmacological role
CYP24A1: human polymorphisms and genome-wide linkage studies
CYP24A1: pathological role and implications in disease
CYP24A1 and genetically-linked idiopathic infantile hypercalcemia
CYP24A1 and genetically-linked hypophosphatemia
CYP24A1: involvement in chronic kidney disease
CYP24A1: involvement in pathogenesis and treatment of hyperproliferative disorders
CYP24A1 inhibitors
 Download the PDF from Sci-Hub via VitaminDWiki

---

Rifampin (an anti-TB drug) reactivated the CYP24A1 gene in one person, stopping Hypercalcemia - May 2022

Long-term efficacy and safety of rifampin in the treatment of a patient carrying a CYP24A1 loss-of-function variant
J Clin Endocrinol Metab . 2022 May 15;dgac315. doi: 10.1210/clinem/dgac315 PDF is behind a $39 paywall and DeepDyve
Alessandro Brancatella 1, Daniele Cappellani 1, Martin Kaufmann 2, Antonella Semeraro 1, Simona Borsari 1, Chiara Sardella 3, Fulvia Baldinotti 4, Maria Adelaide Caligo 4, Glenville Jones 2, Claudio Marcocci 1 3, Filomena Cetani 3

Background: Pharmacological therapy may be useful in the treatment of moderate to severe hypercalcemia in patients with infantile hypercalcemia-1 (HCINF1) due to pathogenic variants in the cytochrome P450 24 subfamily A member 1 (CYP24A1). Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4 (CYP3A4), involved in an alternative catabolic pathway of vitamin D. The efficacy of rifampin in improving hypercalcemia was previously reported but many questions remain on the long-term efficacy and safety. Aim of the study is to test the long-term efficacy and safety of rifampin in a patient with HCINF1.

Methods: We report clinical, biochemical and imaging features of a 23-year-old man affected by HCINF1 with moderate hypercalcemia (12.9 mg/dL), symptomatic nephrolithiasis, nephrocalcinosis and impaired kidney function (eGFR 60 mL/min/1.73 m2) treated with rifampin for an overall period of 24 months. Kidney, liver and adrenal function were evaluated at every follow-up visit.

Results: In 2 months, rifampin induced a normalization of serum calcium (9.6 mg/dL) associated with an improvement of kidney function (eGFR 92 mL/min/1.73 m2) stable during the treatment. After 15 months, rifampin was temporally withdrawn because of asthenia, unrelated to impairment of adrenal function. After three months, the timing of drug administration was shifted from the morning to the evening, obtaining the remission of asthenia. At the end of follow-up, the nephrolithiasis disappeared and the nephrocalcinosis was stable.

Conclusions: Rifampin could represent an effective choice to induce a stable reduction of calcium levels in patients with HCINF1, with a good safety profile.

---

CYP24A1 as a potential target for cancer therapy.- Jan 2014

Anticancer Agents Med Chem. 2014 Jan;14(1):97-108.
Sakaki T, Yasuda K, Kittaka A, Yamamoto K, Chen TC1.

Increasing evidence has accumulated to suggest that vitamin D may reduce the risk of cancer through its biologically active metabolite, 1α,25(OH)2D3, which inhibits proliferation and angiogenesis, induces differentiation and apoptosis, and regulates many other cellular functions. Thus, it is plausible to assume that rapid clearance of 1α,25(OH)2D3 by highly expressed CYP24A1 could interrupt the normal physiology of cells and might be one cause of cancer initiation and progression. In fact, enhancement of CYP24A1 expression has been reported in literature for many cancers. Based on these findings, CYP24A1-specific inhibitors and vitamin D analogs which are resistant to CYP24A1-dependent catabolism might be useful for cancer treatment. CYP24A1-specific inhibitor VID400, which is an azole compound, markedly enhanced and prolonged the antiproliferative activity of 1α,25(OH)2D3 in the human keratinocytes. Likewise, CYP24A1-resistant analogs such as 2α-(3-hydroxypropoxy)-1α,25(OH)2D3 (O2C3) and its C2-epimer ED-71 (Eldecalcitol), and 19nor- 2α-(3-hydroxypropyl)-1α,25(OH)2D3 (MART-10) showed potent biological effects. Our in vivo studies using rats revealed that MART-10 had a low calcemic effect, which is a suitable property as an anticancer drug. Much lower affinity of MART-10 for vitamin D binding protein (DBP) as compared with 1α,25(OH)2D3 may be related to its more potent cellular activities.
Based on these results, we conclude that

• (1) high affinity for VDR,
• (2) resistance to CYP24A1-dependent catabolism,
• (3) low affinity for DBP, and
• (4) low calcemic effect

may be required for designing potent vitamin D analogs for cancer treatment. PMID: 23869781

---

Search Google Scholar for cyp24a1 "vitamin d" 14,600 items

Google Scholar Jan 2025

• Idiopathic infantile hypercalcemia with a CYP24A1 variant triggered by vitamin D supplementation in fortified milk: A case report - Jan 2025 FREE PDF
• Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer - Dec 2020 https://doi.org/10.1007/s11033-020-05780-1
• Bone Metastases of Diverse Primary Origin Frequently Express the VDR (Vitamin D Receptor) and CYP24A1 - Nov 2022 https://doi.org/10.3390/jcm11216537 FREE PDF
• Genetic Polymorphism of Vitamin D Family Genes CYP2R1, CYP24A1, and CYP27B1 Are Associated With a High Risk of Non-alcoholic Fatty Liver Disease: A Case-Control Study - Nov 2021 FREE PDF
• Genetic Variants in CYP2R1, CYP24A1 and VDR Modify the Efficacy of Vitamin D₃ Supplementation for Increasing Serum 25-Hydroxyvitamin D Levels in a Randomized Controlled Trial. - July 2014
• Development of novel Vitamin D Receptor-Coactivator Inhibitors.Feb 2014
• Common variants in CYP2R1 and GC genes predict vitamin D concentrations in healthy Danish children and adults.Feb 2014 full text online
• Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer. Aug 2013
• Stress and vitamin D: Altered vitamin D metabolism in both the hippocampus and myocardium of chronic unpredictable mild stress exposed rats. April 2013
• Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia June 2011 free text here and online
• Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. May 2011 full text on-line
• Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells.- with free paper
• CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. Feb 2011
• Effects of 25-hydroxyvitamin D3 on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1?-hydroxylase.
• Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects.
• Vitamin D pathway gene variants and prostate cancer prognosis.
• Cytochromes P450 are essential players in the vitamin D signaling system.
• CYP24A1 inhibition enhances the antitumor activity of calcitriol.
• Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
• Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet
• Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
• Epigenetic regulation of vitamin D converting enzymes.
• The vitamin D / CYP24A1 story in cancer.
• Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis.
• Asthma and genes encoding components of the vitamin D pathway. - free text

---

CLICK HERE for Clinical Trials of CYP24A1: 25 as of July 2023

---

Clinical trials of Genes and Vitamin D 272 as of July 2023

---

Wikipedia: P450 enzyme group (CYP24A1 is a member of the group)

https://en.wikipedia.org/wiki/Cytochrome_P450 June 2017

Family	Function	Members	Names
CYP1	drug and steroid (especially estrogen) metabolism, benzoapyrene toxification (forming (+)-benzoapyrene-7,8-dihydrodiol-9,10-epoxide)	3 subfamilies, 3 genes, 1 pseudogene	CYP1A1, CYP1A2, CYP1B1
CYP2	drug and steroid metabolism	13 subfamilies, 16 genes, 16 pseudogenes	CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP2W1
CYP3	drug and steroid (including testosterone) metabolism	1 subfamily, 4 genes, 2 pseudogenes	CYP3A4, CYP3A5, CYP3A7, CYP3A43
CYP4	arachidonic acid or fatty acid metabolism	6 subfamilies, 12 genes, 10 pseudogenes	CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4F22, CYP4V2, CYP4X1, CYP4Z1
CYP5	thromboxane A2 synthase	1 subfamily, 1 gene	CYP5A1
CYP7	bile acid biosynthesis 7-alpha hydroxylase of steroid nucleus	2 subfamilies, 2 genes	CYP7A1, CYP7B1
CYP8	varied	2 subfamilies, 2 genes	CYP8A1 (prostacyclin synthase), CYP8B1 (bile acid biosynthesis)
CYP11	steroid biosynthesis	2 subfamilies, 3 genes	CYP11A1, CYP11B1, CYP11B2
CYP17	steroid biosynthesis, 17-alpha hydroxylase	1 subfamily, 1 gene	CYP17A1
CYP19	steroid biosynthesis: aromatase synthesizes estrogen	1 subfamily, 1 gene	CYP19A1
CYP20	unknown function	1 subfamily, 1 gene	CYP20A1
CYP21	steroid biosynthesis	2 subfamilies, 1 gene, 1 pseudogene	CYP21A2
CYP24	vitamin D degradation	1 subfamily, 1 gene	CYP24A1
CYP26	retinoic acid hydroxylase	3 subfamilies, 3 genes	CYP26A1, CYP26B1, CYP26C1
CYP27	varied	3 subfamilies, 3 genes	CYP27A1 (bile acid biosynthesis), CYP27B1 (vitamin D3 1-alpha hydroxylase, activates vitamin D3), CYP27C1 (unknown function)
CYP39	7-alpha hydroxylation of 24-hydroxycholesterol	1 subfamily, 1 gene	CYP39A1
CYP46	cholesterol 24-hydroxylase	1 subfamily, 1 gene	CYP46A1
CYP51	cholesterol biosynthesis	1 subfamily, 1 gene, 3 pseudogenes	CYP51A1 (lanosterol 14-alpha demethylase)

---

There have been 26974 visits to this page